INO$1.71-9.52%
Inovio Pharmaceuticals, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$176.81M
Float & O/S:
Inst Own:
DilutionScan read 61 of INOVIO PHARMACEUTICALS, INC.'s SEC filings and found 7 warrant series, 1 convertible, 1 ATM program, 2 shelf registrations and 3 completed offerings on file for INO. The latest dilution event on file is an offering on Jul 31, 2026. Analysis updated Oct 21, 2026.
Signal8 Summary
INO
FDA approval, but going-concern warning, tiny runway
- Business
- WeakGoing-concern warning, $84.9M net loss, 4.2-month runway
- Stock risk
- High$62M micro-cap, warrants = 94.5% of shares, shares +73% YoY
Snapshot
Inovio is a clinical-stage biotech that just became commercial: FY 2025 revenue was only $65K and the company lost $84.9M. On Nov 2, 2026, VOCERYQ became its first FDA-approved product.
What's Happening Right Now
- : On Nov 2, 2026, Inovio confirmed the FDA granted accelerated approval to VOCERYQ (formerly INO-3107) for recurrent respiratory papillomatosis, the company's first commercial product and the first FDA-approved DNA medicine; shipping is expected in about 60 days with full launch in Q1 2027, and continued approval depends on a confirmatory study due to the FDA by end of 2026.
- : On Oct 20, 2026, Inovio announced it won an $80.4 million judgment against VGXI and GeneOne Life Science on all claims it brought, though collectability and potential appeals remain unaddressed.
- : On Oct 6, 2026, Inovio's board adopted a bylaws amendment naming Delaware Chancery Court and federal courts as exclusive forums for certain shareholder lawsuits, a routine governance change with no disclosed financial impact.
- : On Aug 12, 2026, Inovio reported a Q2 net loss of $6.0M (narrowed from $23.5M), helped heavily by a $13.9M non-cash warrant gain, while FDA review of INO-3107 advanced toward the Oct 30 PDUFA date.
- : Inovio's 10-Q for the quarter ended June 30, 2026 disclosed substantial doubt about its ability to continue operating beyond Q1 2027, with $36.7M in cash plus $18.3M from a July 2026 offering expected to cover only the period through a potential INO-3107 launch; stockholders' equity had fallen to $4.4M against a $1.8B accumulated deficit.
- : Raised $20.00M in gross proceeds through a public offering, with warrants over 48.42M shares.
- : Registered $300.00M of securities for sale on Form S-3.
- : Sold $1.10M net / 667K shares through its at-the-market program, as stated for Jan 1, 2026 to Jun 30, 2026.
